Articles related to Pathology

Gastrointestinal and breast cancer sessions were featured on the first day of the virtual conference, highlighting practice-changing results from a multitude of studies, including the HER2CLIMB, MINDACT, and PHERGAIN trials.

According to study results presented at ASCO20 Virtual Scientific Program, a year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer.

On May 31, 2020, at the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Sessions, late-breaking data dropped for three potentially practice-changing studies: JAVELIN Bladder 100, KEYNOTE-177, and ADAURA.

Already approved to treat ovarian cancer, Rubraca (rucaparib) has been granted accelerated approval as the first PARP inhibitor to treat certain patients with prostate cancer, offering a completely new approach for physicians.

Based on the results of an open-label trial, selpercatinib (Retevmo) becomes the first targeted therapy to be granted accelerated approval by the FDA for use in patients with cancer who have certain tumors that have an alteration (mutation or fusion) in the RET gene.

This roundup of articles highlights the 14 vaccines doctors are targeting in the fight against COVID‑19, in addition to featuring one doctor’s claim that the virus was active in France in December 2019, almost a month earlier than previously believed.